A-A-54227
31 July 1990
COMMERCIAL ITEM DESCRIPTION
DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM INJECTION, USP
The General Services Administration has authorized the use of this Commercial Item Description as a replacement for Military Specification MIL-D-37140C which is cancelled.
Salient characteristics.
Shall be Diatrizoate Meglumine and Diatrizoate Sodium Injection, USP.
Shall be in accordance with the requirements
All ingredients shall be of a pharmaceutical
Strength:
1. 57.6 percent – Diatrizoate Meglumine 28.5 percent and Diatrizoate Sodium 29.1 percent
2. 60 percent - Diatrizoate Meglumine 52 percent and Diatrizoate Sodium 8 percent
3. 69.3 percent - Diatrizoate Meglumine 34.3 percent and Diatrizoate Sodium 35 percent
4. 75 percent - Diatrizoate Meglumine 50 percent and Diatrizoate Sodium 25 percent
5. 76 percent - Diatrizoate Meglumine 66 percent and Diatrizoate Sodium 10 percent
6. 90 percent - Diatrizoate Meglumine 60 percent and Diatrizoate Sodium 30 percent
The sterile, aqueous solution, shall contain the labeled amounts of diatrizoate meglumine and diatrizoate sodium w/v, within the applicable assay limits for the injection.
DISTRIBUTION STATEMENT A. Approved for public release; distribution is unlimited.
For Parts Inquires submit RFQ to Parts Hangar, Inc.
© Copyright 2015 Integrated Publishing, Inc.
A Service Disabled Veteran Owned Small Business